| Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles N Pavlović, S Goločorbin-Kon, M Ðanić, B Stanimirov, H Al-Salami, ... Frontiers in Pharmacology 9, 1283, 2018 | 273 | 2018 |
| Application of bile acids in drug formulation and delivery M Stojančević, N Pavlović, S Goločorbin-Kon, M Mikov Frontiers in Life Science 7 (3-4), 112-122, 2013 | 151 | 2013 |
| Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome M Ðanić, B Stanimirov, N Pavlović, S Goločorbin-Kon, H Al-Salami, ... Frontiers in pharmacology 9, 1382, 2018 | 137 | 2018 |
| The influence of intestinal tract and probiotics on the fate of orally administered drugs M Stojančević, G Bojić, H Al Salami, M Mikov Current issues in molecular biology 16 (1), 55-68, 2014 | 107 | 2014 |
| The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease M Stojancevic, K Stankov, M Mikov Can J Gastroenterol 26 (9), 631-637, 2012 | 85 | 2012 |
| Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of … A Mooranian, R Negrulj, S Mathavan, J Martinez, J Sciarretta, ... Journal of pharmaceutical innovation 9, 150-157, 2014 | 71 | 2014 |
| An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations A Mooranian, R Negrulj, S Mathavan, J Martinez, J Sciarretta, ... Pharmaceutical development and technology 20 (6), 702-709, 2015 | 67 | 2015 |
| Semisynthetic bile acids: a new therapeutic option for metabolic syndrome S Lazarević, M Đanić, S Goločorbin-Kon, H Al-Salami, M Mikov Pharmacological research 146, 104333, 2019 | 47 | 2019 |
| Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics M Mikov, M Đanić, N Pavlović, B Stanimirov, S Goločorbin-Kon, K Stankov, ... European Journal of Drug Metabolism and Pharmacokinetics 43, 269-280, 2018 | 33 | 2018 |
| An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden N Pavlović, B Stanimirov, M Stojančević, M Paut-Kusturica, A Stoimenova, ... Biotechnology & Biotechnological Equipment 26 (5), 3236-3241, 2012 | 28 | 2012 |
| Probiotics as a promising treatment for inflammatory bowel disease MM Mikov, MP Stojančević, GM Bojić Hosp Pharmacol 1 (1), 52-60, 2014 | 24 | 2014 |
| PAMPA model of gliclazide permeability: The impact of probiotic bacteria and bile acids M Đanić, N Pavlović, B Stanimirov, S Lazarević, S Vukmirović, ... European Journal of Pharmaceutical Sciences 158, 105668, 2021 | 23 | 2021 |
| DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment M Mikov, N Pavlović, B Stanimirov, M Đanić, S Goločorbin-Kon, K Stankov, ... European journal of drug metabolism and pharmacokinetics 45 (1), 1-14, 2020 | 21 | 2020 |
| The influence of bile salts on the distribution of simvastatin in the octanol/buffer system M Đanić, N Pavlović, B Stanimirov, S Vukmirović, K Nikolić, D Agbaba, ... Drug Development and Industrial Pharmacy 42 (4), 661-667, 2016 | 18 | 2016 |
| The role of drug metabolites in the inhibition of cytochrome P450 enzymes M Mikov, M Đanić, N Pavlović, B Stanimirov, S Goločorbin-Kon, K Stankov, ... European Journal of Drug Metabolism and Pharmacokinetics 42 (6), 881-890, 2017 | 17 | 2017 |
| Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteria. M Djanic, N Pavlovic, B Stanimirov, T Stojancevic, S Golocorbin-Kon, ... European Review for Medical & Pharmacological Sciences 20 (3), 2016 | 17 | 2016 |
| The effect of deoxycholic acid on chitosan-enabled matrices for tissue scaffolding and injectable nanogels B Kovacevic, CM Ionescu, M Jones, SR Wagle, M Lewkowicz, M Đanić, ... Gels 8 (6), 358, 2022 | 15 | 2022 |
| Transport and biotransformation of gliclazide and the effect of deoxycholic acid in a probiotic bacteria model M Ðanić, B Stanimirov, N Pavlović, S Vukmirović, J Lazić, H Al-Salami, ... Frontiers in pharmacology 10, 1083, 2019 | 15 | 2019 |
| Gut microbiota metabolism of Azathioprine: A new hallmark for personalized drug-targeted therapy of chronic inflammatory bowel disease S Lazarević, M Đanic, H Al-Salami, A Mooranian, M Mikov Frontiers in Pharmacology 13, 879170, 2022 | 14 | 2022 |
| Drug interference with biochemical laboratory tests J Katanić, B Stanimirov, V Sekeruš, M Đanić, N Pavlović, M Mikov, ... Biochemia Medica 33 (2), 2023 | 13 | 2023 |
Momir MikovProfessor Pharmacology and Toxicology, Medical Faculty, University of Novi Sad, SerbiaE-mail confirmado em mf.uns.ac.rs
